About the Author: Bharat Jasani, BSc, PhD, MBChB, FRCPath, qualified with honours in Biochemistry (University of Glasgow,1965-1969), PhD in Experimental Pathology and MBChB (honours distinction in Pathology) (University of Birmingham, 1970-1976), to initiate his clinical and research training in Histopathology, at Wales National School of Medicine in 1977, achieving MRCPath (1989), FRCPath (1997), and a Specialist Consultant's status in Histopathology (Immunohistochemistry) (1993); followed by Personal Chair in Oncological Pathology (2003). and Headship of the University Hospital Wales Histopathology and Academic Pathology Department (2003-2011). Following his retirement in 2011, he continued as Professor of Pathology, Institute of Cancer & Genetics, Cardiff University & Associate Postgraduate Dean for Academic Medicine in Wales until 2015 when he was appointed the Chair of Biomedical Sciences, Nazarbayev University School of Medicine. Astana, Kazakhstan, with Adjunct Professorship in Pathology, University of Pittsburgh School of Medicine, Pittsburg, USA. In 2016 he was headhunted to take up his current position as the Director of Pathology, Targos Molecular Pathology GmbH, Kassel, Germany. Over his 40 years of service as a pathologist, Dr Jasani devoted himself to advancing cancer pathology through the use of cancer biomarkers starting as the Head of Molecular Diagnostic Unit, University Hospital of Wales (1982-2003), developing and establishing the first diagnostic immunocytochemistry & molecular pathology services in Cardiff and Wales. At the national level he promoted quality assurance and standardization of cancer biomarker analyses as Breast Cancer Module Leader of UKNEQAS of IHC/ISH, and at the international level as UK's lead representative on International Working Group on Standardization of Breast Cancer Biomarking, and the United States Sub-Committee on Quality Assurance for Immunocytochemistry. During this period he led several translational research projects on development of predictive biomarkers for colorectal and breast cancer, at the same acting as a Consultant and Key Opinion Leader to several leading biotech and pharmaceutical companies, and authoring a book, and writing over 50 chapters and reviews and over 225 peer reviewed research publications. His work also led to the patenting of the highly sensitive DNP-hapten sandwich and diaminobenzidine silver detection systems and the invention of the use of the autoclave and EDTA based antigen retrieval methods, and LR White tissue embedding for correlative LM/EM immunohistochemistry.
Ralf Huss, M.D., Ph.D. Ralf Huss holds an M.D. degree from the University of Erlangen-Nuremberg, and Ph.D. degree from the Ludwig-Maximilians-University Munich. Following internships and residencies in Medicine, Immunology and Transplantation Biology at the Memorial-Sloan-Kettering Cancer Center in NYC, the University Hospital in Zurich, Switzerland and the Fred Hutchinson Cancer Research Center in Seattle, WA, Dr. Huss was appointed senior resident at the Institute of Immunology in Essen, Germany in 1994, before he moved to the Ludwig-Maximilians-University in Munich to complete his training in anatomical, surgical and molecular pathology. In 2005 he was appointed Global Head of Pathology and Tissue Biomarker at the Pharmaceutical company Roche (Switzerland and Germany). After pioneering the integration of image analysis and computational pathology into the clinical histopathology workflow together with the Nobel Laureate Gerd Binnig at Definies / AstraZeneca, in 2020, Dr. Huss returned to academia and is currently Professor and Deputy Director at the Institute of Pathology and Molecular Diagnostics and at the Institute for Digital Medicine, University Hospital Augsburg, Germany. Professor Huss has published more than 150 scientific papers and 4 books in the fields of cell therapy, tissue phenomics and artificial intelligence in pathology. Dr. Huss holds several patents and has served as a Board member and / or consultant to a number of private and public corporations.
Clive Roy Taylor, M.D., D. Phil., MRCP (Ir), FRCPath. Clive Taylor holds M.A. and M.D. degrees from the University of Cambridge, and M.A. and D. Phil degrees from the University of Oxford. Following internships in Medicine and Surgery at the Radcliffe Infirmary, Oxford, Dr. Taylor was appointed Lecturer at the University of Oxford, in 1970. A " Fellowship" in Cancer Research took Dr. Taylor to the University of Southern California (USC) in 1975, where he worked on lymphoma with Robert Lukes. In 1984 he was appointed to the Chair of the Department of Pathology and Laboratory Medicine at USC, a position that he held for 25 years. In 1998 Professor Taylor also accepted the post of Senior Associate Dean for Educational Affairs at the Keck School of Medicine, USC, a role that he filled until July 2009. Professor Taylor is a Fellow of the Royal College of Pathologists (U.K.), a Diplomate of the American Board of Pathology, and a Member of the Royal College of Physicians (Ireland). He was President of the U.S. Association of Pathology Chairs from 1996-1999, President of the U.S. Biological Stain Commission, from1994 - 1998, and is a member of the Royal Society of Medicine (UK). Professor Taylor Chaired an FDA Advisory Panel for Diagnostic Devices and Radiology until 2007. Professor Taylor has published more than 450 scientific papers and 12 books, in the fields of immunohistochemistry, cancer, lymphoma research, digital pathology and education. Dr. Taylor holds several patents, is Editor-in-Chief of Applied Immunohistochemistry and Molecular Morphology, and has served as a Board member and / or consultant to a number of private and public corporations.
